Categories: BionicNews

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

Paris, France, January 17, 2024 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the Company as soon as it becomes aware of it.

Pixium draws investors’ attention to the fact that, given the price offered by the prospective buyer and the Company’s level of indebtedness, the sale proceeds received in the event of a favourable decision by the Commercial Court will not allow a total or partial reimbursement of shareholders.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

               www.linkedin.com/company/pixium-vision  

Contacts

Investor Relations

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com

Media Relations

Rose Piquante Consulting
Sophie Baumont
Sophie.baumont@rosepiquante-consulting.com
+33 6 27 74 74 49

 

Attachment

Staff

Recent Posts

Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities

Important note: Biophytis has set up financing in the form of Bonds redeemable in cash…

4 hours ago

Watertown Regional Medical Center Partners with HOPCo To Enhance Orthopedic and Spine Services

WATERTOWN, Wis. and PHOENIX, Ariz., June 19, 2024 /PRNewswire/ -- Watertown Regional Medical Center (WRMC)…

7 hours ago

Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024

SECAUCUS, N.J., June 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic…

7 hours ago

MULTI GRAMMY AWARD-WINNING ARTIST LIZZO KICKS OFF 5TH ANNUAL JUNETEENTH GIVEBACK FEATURING IMPACTFUL INITIATIVES AND INSPIRING CONVERSATIONS

LOS ANGELES, June 19, 2024 /PRNewswire/ -- For the fifth consecutive year, multi-Grammy Award and…

7 hours ago

MediOrbis(TM) Partners with Healthyr(TM) to Offer Proven Engagement, Longitudinal Care and Specialty

MediOrbis TM Partners with Healthyr to Offer Proven Engagement, Longitudinal Care and Specialty Telehealth Services…

10 hours ago

Humhealth Simplifies the Medicare Program With All-in-One Software

WIXOM, MI / ACCESSWIRE / June 19, 2024 / Humhealth has emerged as a software…

10 hours ago